Viemed Healthcare (NASDAQ:VMD) Cut to Buy at Wall Street Zen

Wall Street Zen downgraded shares of Viemed Healthcare (NASDAQ:VMD) from a strong-buy rating to a buy rating in a report published on Saturday.

A number of other analysts have also issued reports on the stock. Weiss Ratings upgraded shares of Viemed Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, August 3rd. Freedom Capital lowered shares of Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Viemed Healthcare presently has a consensus rating of “Hold”.

Viemed Healthcare Trading Down 1.6%

Shares of NASDAQ VMD opened at $9.05 on Friday. Viemed Healthcare has a twelve month low of $6.05 and a twelve month high of $12.61. The company has a current ratio of 1.13, a quick ratio of 1.02 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $11.08 and a 200-day simple moving average of $9.84. The stock has a market capitalization of $344.71 million, a PE ratio of 25.14 and a beta of 1.10.

Viemed Healthcare (NASDAQ:VMD) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. The firm had revenue of $78.10 million during the quarter, compared to analysts’ expectations of $78.00 million. On average, equities analysts forecast that Viemed Healthcare will post 0.42 earnings per share for the current year.

Insider Buying and Selling at Viemed Healthcare

In other news, Director Timothy Smokoff sold 20,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $11.50, for a total value of $230,000.00. Following the sale, the director directly owned 75,518 shares in the company, valued at approximately $868,457. This trade represents a 20.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Frazier sold 10,000 shares of Viemed Healthcare stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.72, for a total value of $117,200.00. Following the completion of the transaction, the insider owned 73,214 shares of the company’s stock, valued at approximately $858,068.08. This trade represents a 12.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 20.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VMD. BlackRock Inc. acquired a new stake in shares of Viemed Healthcare in the 2nd quarter valued at $54,587,000. Punch & Associates Investment Management Inc. acquired a new position in shares of Viemed Healthcare during the second quarter worth $6,082,000. Raffles Associates LP purchased a new position in Viemed Healthcare in the second quarter valued at $4,602,000. Arrowstreet Capital Limited Partnership raised its stake in Viemed Healthcare by 101.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 711,186 shares of the company’s stock valued at $6,550,000 after buying an additional 358,863 shares in the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new position in shares of Viemed Healthcare in the 2nd quarter valued at about $3,900,000. Institutional investors and hedge funds own 74.24% of the company’s stock.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.